Interleukin 10 treatment for rheumatoid arthritis.

نویسنده

  • E W St Clair
چکیده

Interleukin (IL) 10 looms as a highly promising treatment for rheumatoid arthritis (RA) because of its capacity to inhibit cellular immunity and deactivate macrophages. In RA, activated CD4 T helper cells and macrophages are believed to be the primary driving force behind joint inflammation. Synovial macrophages play a critical part in stimulating synovial inflammation. They produce abundant quantities of proinflammatory cytokines such as IL1 and tumour necrosis factor (TNF) á. The body attempts to keep the inflammatory response in check by upregulating the synthesis of endogenous inhibitors such as IL1 receptor antagonist (ra), soluble TNF receptors (TNFR), and IL10. These inhibitors act in concert to dampen the inflammatory response. IL10 is relatively unique in its ability to downregulate the production of multiple pro-inflammatory cytokines, leading to the notion that IL10 would be an eVective treatment for RA.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

second patient with seronegative rheumatoid arthritis and treatment with diet

second patient with seronegative rheumatoid arthritis and treatment with diet

متن کامل

The Effect of Human Recombinant Tumor Necrosis Factor Receptor-2 on Reducing Inflammatory of Collagen -Induced Arthritis in Balb/c Mice

Background: The tumor necrosis factor alpha (TNFα) is a cytokine that produced principally by monocyte/macrophages and T lymphocytes, respectively. TNFα is recognized as the primary mediator of immunity in inflammation reaction.  One important application of Tumor Necrosis Factor Receptor 2 (TNFR2) is for the treatment of autoimmune diseases like rheumatoid arthritis (RA).<br /...

متن کامل

Rheumatoid Arthritis: Early diagnosis and treatment outcomes

Rheumatoid arthritis (RA) is an inflammatory progressive disease which in the absence of appropriate treatment can lead to joint destruction and disability. Prognosis of RA may be predicted based on the presence of some clinical and laboratory evidences.New criteria for classification of RA provides opportunity for earlier treatment. Initiation of treatment particularly by combination of DMARDs...

متن کامل

New advances in interleukin-1 blockade for the treatment of rheumatoid arthritis

10.2217/14750708.2.3.439 © 2 part of Rheumatoid arthritis is a relatively common systemic inflammatory disease, which has a substantial impact on patient functioning and survival. The etiology of rheumatoid arthritis has not been completely elucidated, but proinflammatory cytokines, such as interleukin-1, have been implicated as important pathogenic players. These cytokines ultimately lead to i...

متن کامل

Serum Levels of TNF-α, TNF-αRI, TNF-αRII and IL-12 in Treated Rheumatoid Arthritis Patients

Background: Rheumatoid arthritis (RA) is a chronic multisystem autoimmune disease common in all races and ethnics. Cytokines and cytokines receptors play an important role in RA pathogenesis and clinical presentation. Objective: To investigate the serum levels of TNF-α, TNF-α RI, TNF-α RII and IL-12 in RA patients and healthy control group. Methods: In this study 43 patients fulfilling the revi...

متن کامل

Effect of Losartan in Complete Freund’s Adjuvant –Induced Arthritis in Rats

Rheumatoid arthritis (RA) is an autoimmune inflammatory disease characterized by joint infiltration and bone damage. The aim of the present study was to evaluate the beneficial effects of losartan in adjuvant-induced arthritis (AIA). Arthritis was induced in rats by subcutaneous injection of 0.2ml of Complete Freund’s adjuvant (CFA) in the planter surface of the hind paw. Arthritic rats were al...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:
  • Annals of the rheumatic diseases

دوره 58 Suppl 1  شماره 

صفحات  -

تاریخ انتشار 1999